Shares of Kyverna Therapeutics (NASDAQ:KYTX) are down almost 13% in Friday afternoon trading, changing hands near $8.60 after opening the session at $9.81. The pullback interrupts a strong run for the clinical-stage autoimmune CAR-T developer, which is still up 25% over the past month and 215% over the past year.
Analyst Target Cut Cools a Hot Trade
The catalyst appears to be a fresh analyst note. JPMorgan reiterated its Overweight rating but trimmed its price target on the stock to $29, while Weiss Ratings and Wall Street Zen issued sell calls. The consensus still sits at Moderate Buy with an average target of $30, but the reset in expectations is landing hard on a stock that had tripled off last summer’s lows.
The move is notable because it comes despite reasonable results for a clinical-stage biotech. Kyverna reported a Q1 2026 loss of -$0.66 per share, better than the -$0.73 consensus. The company also initiated a rolling BLA submission for lead asset miv-cel in stiff person syndrome, with completion expected Q4 2026 and potential commercial launch in 2027. CEO Warner Biddle called the FDA alignment on a single-arm trial “a significant milestone” in the company’s May filing.
Cell-Therapy Peers Also Under Pressure
The broader autoimmune and oncology cell-therapy group is soft on the session alongside Kyverna. Cabaletta Bio (NASDAQ:CABA), which recently raised $150 million with Eli Lilly participating, is off 4%. Allogene Therapeutics (NASDAQ:ALLO), fresh off strong ALPHA3 data earlier this summer, is down 5%. Beam Therapeutics (NASDAQ:BEAM | BEAM Price Prediction) is the weakest of the group, sliding 8% from a recent 52-week high. Cartesian Therapeutics (NASDAQ:RNAC), Kyverna’s most direct competitor in myasthenia gravis, is holding up better, down only 1%.
After a month in which Kyverna joined the Russell 2000 and Russell 3000 indexes, hired a new CFO and Chief Legal Officer, and drew a 33.3% stake increase from AIGH Capital, expectations had run ahead of the setup. A single price-target trim was enough to trigger profit-taking in a low-float, high-beta name. Kyverna’s beta sits at 1.88, and shares still trade well below the 52-week high of $13.67.
What to Watch
The next scheduled catalyst is Q2 2026 earnings on August 11, 2026, with consensus at -$0.67. Before then, investors will look for updates on the rolling BLA submission for miv-cel and longer-term Phase 2 gMG follow-up data guided for H2 2026. I would keep an eye on whether KYTX can hold the $8.72 50-day moving average into the close.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks